Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.
APECS is a randomized, placebo-controlled, parallel-group, double-blind Phase 3 clinical trial evaluating the efficacy and safety of verubecestat in people with prodromal AD.
Amyloid beta (Aβ) deposits in Alzheimer's patients might also negatively affect their heart muscle and increase their risk of heart failure, according to a study published in the Journal of the American College of Cardiology.
Benzodiazepines and related drugs were found to increase the risk of hip fracture in patients with Alzheimer's disease.
Eli Lilly announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION3 clinical trial in patients with mild dementia due to Alzheimer's disease.
Eisai announced that the Food and Drug Administration (FDA) has granted Fast Track designation for E2609 (Eisai and Biogen) in development for early Alzheimer's disease.
Elderly people who experience chronic stress are twice as likely to develop mild cognitive impairment, which is a common prelude to full-blown Alzheimer's disease.
Patients with early-stage Alzheimer's disease who consume two to three alcoholic drinks a day may have a reduced risk of mortality compared to those who consume one or fewer drinks a day, according to a study published online December 11 in BMJ Open.
Apigenin, a flavonoid found in some spices and herbs, may improve neuron formation and strengthen connections between brain cells, researchers from D'Or Institute for Research and Education reported.
Seniors who walk more slowly may have higher amounts β-amyloid (Aβ) in their brains, according to research published online in Neurology.
Raloxifene does not appear to have a beneficial effect on memory and thinking skills in women with dementia due to Alzheimer's disease, a recent study has shown.
Targeted stimulation of the immune system in mice has led to the removal of amyloid plaque formation, (a known marker of Alzheimer's disease), according to researchers at NYU Langone Medical Center.